DK1742950T3 - Pyrazolo-[4,3-D]-pyrimidiner - Google Patents

Pyrazolo-[4,3-D]-pyrimidiner

Info

Publication number: DK1742950T3
Authority: DK; Denmark
Prior art keywords: pyrazolo; pyrimidines; compounds; formula; relates
Prior art date: 2004-04-07

Application number

DK05718362T

Other languages

Danish (da)

English (en)

Inventor

Andrew Simon Bell

David Graham Brown

David Nathan Abraham Fox

Hwang-Fun Lu

Ian Roger Marsh

Andrew Ian Morrell

Dafydd Rhys Owen

Michael John Palmer

Thomas Edward Rogers

Carol Ann Windslow

Original Assignee

Pfizer Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-07

Filing date

2005-03-30

Publication date

2009-03-16

2004-04-07 Priority claimed from GB0407927A external-priority patent/GB0407927D0/en

2004-04-07 Priority claimed from GB0407946A external-priority patent/GB0407946D0/en

2005-03-30 Application filed by Pfizer Ltd filed Critical Pfizer Ltd

2009-03-16 Application granted granted Critical

2009-03-16 Publication of DK1742950T3 publication Critical patent/DK1742950T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Pregnancy & Childbirth (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK05718362T 2004-04-07 2005-03-30 Pyrazolo-[4,3-D]-pyrimidiner DK1742950T3 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB0407927A GB0407927D0 (en)	2004-04-07	2004-04-07	Novel pharmaceuticals
GB0407946A GB0407946D0 (en)	2004-04-07	2004-04-07	Novel pharmaceuticals
US57204904P	2004-05-18	2004-05-18
US57202404P	2004-05-18	2004-05-18
PCT/IB2005/000891 WO2005097799A1 (fr)	2004-04-07	2005-03-30	Pyrazolo`4,3[4,3-d]pyrimidines

Publications (1)

Publication Number	Publication Date
DK1742950T3 true DK1742950T3 (da)	2009-03-16

Family

ID=34962202

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05718362T DK1742950T3 (da)	2004-04-07	2005-03-30	Pyrazolo-[4,3-D]-pyrimidiner

Country Status (10)

Country	Link
US (1)	US7569572B2 (fr)
EP (1)	EP1742950B1 (fr)
JP (1)	JP2007532526A (fr)
AT (1)	ATE417849T1 (fr)
BR (1)	BRPI0509731A (fr)
CA (1)	CA2562251C (fr)
DE (1)	DE602005011784D1 (fr)
DK (1)	DK1742950T3 (fr)
ES (1)	ES2317209T3 (fr)
WO (1)	WO2005097799A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU714980B2 (en)	1996-07-24	2000-01-13	Warner-Lambert Company Llc	Isobutylgaba and its derivatives for the treatment of pain
BRPI0609225A2 (pt)	2005-05-12	2010-03-09	Pfizer	formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
NL2000291C2 (nl) *	2005-11-10	2009-02-17	Pfizer Prod Inc	1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
WO2010062308A1 (fr) *	2008-10-28	2010-06-03	The Board Of Trustees Of The Leland Stanford Junior University	Modulateurs d’aldéhyde déshydrogénase et procédés d’utilisation de ceux-ci
DE102008063992A1 (de) *	2008-12-19	2010-09-02	Lerner, Zinoviy, Dipl.-Ing.	Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
UY33535A (es)	2010-08-13	2011-12-01	Biolab Sanus Farmaceutuca Limitada	Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona
WO2012149106A1 (fr)	2011-04-29	2012-11-01	The Board Of Trustees Of The Leland Stanford Junior University	Compositions et procédés d'augmentation de la prolifération de cellules souches salivaires adultes
WO2014081958A1 (fr)	2012-11-21	2014-05-30	Cardiomems, Inc.	Dispositifs, systèmes et méthodes d'évaluation et de traitement de l'hypertension artérielle pulmonaire (htap)
JP6410790B2 (ja)	2013-03-14	2018-10-24	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
US9198908B2 (en) *	2013-03-15	2015-12-01	St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”)	Methods for the treatment of cardiovascular conditions
WO2015171489A1 (fr) *	2014-05-05	2015-11-12	Apicore Us Llc	Procédés de fabrication de nétupitant et d'intermédiaires de celui-ci

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3851980A (en) *	1974-04-19	1974-12-03	L Worth	Tubing connector
US3951980A (en)	1974-05-09	1976-04-20	Stanford Research Institute	3-Substituted-8-methyl-3,8-diazabicyclo[3.2.1]octanes
US4282361A (en) *	1978-03-16	1981-08-04	Massachusetts Institute Of Technology	Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
AU516604B2 (en)	1978-04-03	1981-06-11	Yoshida Kogyo K.K.	Tiltable roller assembly
DE3687030T2 (de)	1985-03-15	1993-03-11	Eugene Stirchak	Stereoregulare polynukleotiden bindende polymere.
US4812590A (en)	1987-06-25	1989-03-14	Merck & Co., Inc.	Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
WO1989000158A1 (fr)	1987-07-02	1989-01-12	Pfizer Inc.	Acides et esters carboxyliques de quinolone de diazabicycloalkyle shunte
GB8728483D0 (en)	1987-12-04	1988-01-13	Ciba Geigy Ag	Chemical compounds
US5091431A (en)	1988-02-08	1992-02-25	Schering Corporation	Phosphodiesterase inhibitors
US5075310A (en)	1988-07-01	1991-12-24	Smith Kline & French Laboratories, Ltd.	Pyrimidone derivatives as bronchodilators
FR2638745B1 (fr)	1988-11-08	1994-01-14	Synthelabo	Derives de ((n-alkylthioalkyl-methylamino)-2 ethyl)-5 benzothiazepine-1,5 one-4, leur preparation et leur application en therapeutique
US4994460A (en)	1989-06-01	1991-02-19	Bristol-Myers Squibb Co.	Agents for treatment of brain ischemia
JPH03142277A (ja)	1989-10-30	1991-06-18	Fuji Photo Film Co Ltd	記録材料
US5442044A (en)	1991-01-04	1995-08-15	Pfizer Inc.	Orally active renin inhibitors
DE69217224T2 (de)	1991-07-03	1997-06-05	Pharmacia & Upjohn Co., Kalamazoo, Mich.	Substituierte indole als anti-aids pharmaceutische zubereitungen
GB9119704D0 (en)	1991-09-14	1991-10-30	Pfizer Ltd	Therapeutic agents
GB9121028D0 (en)	1991-10-03	1991-11-13	Pfizer Ltd	Therapeutic agents
GB9126260D0 (en)	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
GB9213623D0 (en)	1992-06-26	1992-08-12	Pfizer Ltd	Therapeutic agents
JP2657760B2 (ja)	1992-07-15	1997-09-24	小野薬品工業株式会社	４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9218322D0 (en)	1992-08-28	1992-10-14	Pfizer Ltd	Therapeutic agents
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
GB9423911D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
US5869486A (en)	1995-02-24	1999-02-09	Ono Pharmaceutical Co., Ltd.	Fused pyrimidines and pyriazines as pharmaceutical compounds
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
DE19644228A1 (de)	1996-10-24	1998-04-30	Merck Patent Gmbh	Thienopyrimidine
CZ299633B6 (cs)	1997-04-25	2008-09-24	Pfizer Inc.	Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi
US6184338B1 (en)	1997-08-27	2001-02-06	Fmc Corporation	Anionic polymerization initiators containing tertiary amine functionality, their chain extended analogues, and processes for using the same
DK1174431T3 (da)	1997-11-12	2012-08-20	Bayer Pharma AG	2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer
DE19752952A1 (de)	1997-11-28	1999-06-02	Merck Patent Gmbh	Thienopyrimidine
CA2260499A1 (fr)	1998-01-29	1999-07-29	Sumitomo Pharmaceuticals Company Limited	Compositions pharmaceutiques pour le traitement de dommages ischemiques au cerveau
GB9804426D0 (en)	1998-03-02	1998-04-29	Pfizer Ltd	Heterocycles
ATE247117T1 (de)	1998-04-20	2003-08-15	Pfizer	Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DK1123296T3 (da)	1998-10-23	2003-12-08	Pfizer	Pyrazolopyrimidinon cGMP PDE5-inhibitorer til behandling af seksuel forstyrrelse
AU3514200A (en)	1999-03-10	2000-09-28	Merck & Co., Inc.	6-azaindole compounds as antagonists of gonadotropin releasing hormone
US6465486B1 (en)	1999-03-12	2002-10-15	Ortho-Mcneil Pharmaceutical, Inc.	Pyridyl/quinolinyl imidazoles
GB9912415D0 (en)	1999-05-28	1999-07-28	Pfizer Ltd	Compounds useful in therapy
DE19942474A1 (de)	1999-09-06	2001-03-15	Merck Patent Gmbh	Pyrazolo[4,3-d]pyrimidine
CZ20021086A3 (cs)	1999-09-30	2002-10-16	Neurogen Corporation	Alkylendiaminem substituované heterocykly
JP2003511452A (ja)	1999-10-11	2003-03-25	ファイザー・インク	ホスホジエステラーゼ阻害剤としての５−（２−置換−５−ヘテロシクリルスルホニルピリド−３−イル）−ジヒドロピラゾロ［４，３−ｄ］ピリミジン−７−オン
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6548509B2 (en)	1999-10-22	2003-04-15	Neurogen Corporation	3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
GB9926302D0 (en)	1999-11-05	2000-01-12	Smithkline Beecham Plc	Novel compounds
GB9930570D0 (en)	1999-12-23	2000-02-16	Pfizer Ltd	Therapy
CZ20022047A3 (cs)	1999-12-23	2003-09-17	Pfizer Products Inc.	Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva
EP1244668B1 (fr)	2000-01-07	2006-04-05	Universitaire Instelling Antwerpen	Derives de purine, procede de preparation et utilisation de ces derniers
US20010047013A1 (en)	2000-03-10	2001-11-29	Fengrui Lang	Process for the preparation of arylamines
DE10031584A1 (de)	2000-06-29	2002-01-10	Merck Patent Gmbh	5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
WO2002010171A1 (fr)	2000-07-28	2002-02-07	Pfizer Limited	Agent therapeutique cristallin
EP1176142A1 (fr)	2000-07-28	2002-01-30	Pfizer Inc.	Procédé pour la préparation de pyrazoles
EP1176147A1 (fr)	2000-07-28	2002-01-30	Pfizer Limited	Procédé de préparation de pyrazolo[4,3-d]pyrimidin-7-ones et de leurs intermédiaires
CA2419033A1 (fr)	2000-08-11	2002-02-21	Earl Michael Gibbs	Traitement du syndrome de la resistance a l'insuline
US6821966B2 (en)	2000-11-20	2004-11-23	Scios, Inc.	Inhibitors of p38 kinase
DE10058662A1 (de)	2000-11-25	2002-05-29	Merck Patent Gmbh	Verwendung von Pyrazolo[4,3-d]pyrimidinen
MXPA03005393A (es)	2000-12-19	2003-09-25	Merck Patent Gmbh	Formulacion farmaceutica que contiene pirazolo (4,3-d) pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina.
JP2004517940A (ja)	2001-01-31	2004-06-17	メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング	ピラゾロ［４，３−ｄ］ピリミジンおよびニトレートまたはチエノピリミジンおよびニトレートを含む医薬製剤
GB0103926D0 (en)	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
JP2002255932A (ja)	2001-03-01	2002-09-11	Katayama Seiyakushiyo:Kk	３−アルキルアミノアゼチジンの製造方法
US20020127593A1 (en)	2001-03-12	2002-09-12	Regents Of The University Of California	Fluorescence assay for DNA modifying enzymes
GB0106631D0 (en)	2001-03-16	2001-05-09	Pfizer Ltd	Pharmaceutically active compounds
PE20030008A1 (es)	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
US6432957B1 (en)	2001-06-29	2002-08-13	Kowa Co., Ltd.	Piperazine derivative
DE60329375D1 (en)	2002-03-15	2009-11-05	Univ Wayne State	Neue 2-amino-9-((2-hydroxymethyl)cyclopropylidenmethyl)-purine als antivirale mittel
ATE478872T1 (de)	2002-03-28	2010-09-15	Ustav Ex Botan Av Cr V V I I O	Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
US7505971B2 (en)	2002-06-28	2009-03-17	Hewlett-Packard Development Company, L.P.	Shared drive that provides shared access to editable files in a database
DK1620437T3 (da)	2003-04-29	2009-08-24	Pfizer Ltd	5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension

2005
- 2005-03-30 US US10/599,702 patent/US7569572B2/en not_active Expired - Fee Related
- 2005-03-30 WO PCT/IB2005/000891 patent/WO2005097799A1/fr not_active Ceased
- 2005-03-30 EP EP05718362A patent/EP1742950B1/fr not_active Expired - Lifetime
- 2005-03-30 BR BRPI0509731-2A patent/BRPI0509731A/pt not_active IP Right Cessation
- 2005-03-30 ES ES05718362T patent/ES2317209T3/es not_active Expired - Lifetime
- 2005-03-30 DK DK05718362T patent/DK1742950T3/da active
- 2005-03-30 CA CA002562251A patent/CA2562251C/fr not_active Expired - Fee Related
- 2005-03-30 DE DE602005011784T patent/DE602005011784D1/de not_active Expired - Fee Related
- 2005-03-30 AT AT05718362T patent/ATE417849T1/de not_active IP Right Cessation
- 2005-03-30 JP JP2007506858A patent/JP2007532526A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CA2562251C (fr)	2009-04-28
EP1742950B1 (fr)	2008-12-17
BRPI0509731A (pt)	2007-09-25
ES2317209T3 (es)	2009-04-16
DE602005011784D1 (de)	2009-01-29
US20080293697A1 (en)	2008-11-27
WO2005097799A1 (fr)	2005-10-20
WO2005097799A8 (fr)	2006-02-16
EP1742950A1 (fr)	2007-01-17
CA2562251A1 (fr)	2005-10-20
JP2007532526A (ja)	2007-11-15
US7569572B2 (en)	2009-08-04
ATE417849T1 (de)	2009-01-15

Publication	Publication Date	Title
EA200600677A1 (ru)	2006-12-29	5,7-диаминопиразоло[4,3-d]пиримидины c ингибирующей pde-5 активностью
MXPA05011643A (es)	2005-12-15	5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
TNSN07323A1 (en)	2008-12-31	Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors
IL160915A0 (en)	2004-08-31	Indolizines inhibiting kinase proteins
MXPA05012025A (es)	2006-02-03	Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
TW200626559A (en)	2006-08-01	Anilino-pyrimidine analogs
ATE430747T1 (de)	2009-05-15	2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
EA200870116A1 (ru)	2009-10-30	Бициклические гетероарильные соединения
EP2078721A3 (fr)	2009-07-22	Composés thiéno-pyrimidines ayant une activité fongicide
DE60314623D1 (de)	2007-08-09	Substituierte pyrazolopyrimidine
MX2007003108A (es)	2007-05-24	Compuestos imidazo-3-il-amina sustituidos y biciclicos.
TW200728277A (en)	2007-08-01	Bicyclic derivatives as P38 inhibitors
ATE438398T1 (de)	2009-08-15	Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren
ATE516291T1 (de)	2011-07-15	Thenopyrimidin-verbindungen mit fungizider aktivität
DK1742950T3 (da)	2009-03-16	Pyrazolo-[4,3-D]-pyrimidiner
MX2008011576A (es)	2008-09-22	Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.
EA200702071A1 (ru)	2008-02-28	Новые соединения
ATE387449T1 (de)	2008-03-15	Pyrazolopyrimidine
WO2007000340A3 (fr)	2007-03-29	Derives bicycliques utilises en tant qu'inhibiteurs de kinase p38
WO2009006267A3 (fr)	2009-04-16	N'-(2-halobenzylidene)sulfonylhydrazides en tant qu'intermédiaires dans la fabrication d'arylsulfonylindazoles
DE602004030231D1 (de)	2011-01-05	Pyrimidinonverbindungen als calcilytica
DK1948661T3 (da)	2009-09-07	Pyrazolo[4,3-D]pyrimidin-5-YL)-derivat anvendt som PDE5-inhibitorer
WO2007000337A8 (fr)	2007-04-19	Derives bicycliques utilises en tant qu'inhibiteurs de p38 kinase
UA80871C2 (en)	2007-11-12	5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension
TW200745115A (en)	2007-12-16	7-Amino-6-heteroaryl-1,2,4-triazolo[1,5-a]pyrimidine compounds and their use for controlling harmful fungi